Stealth BioTherapeutics Looks Ahead To Phase III In Mitochondrial Disease
Executive Summary
Stealth BioTherapeutics is planning Phase III trials on the back of positive Phase II data for its lead product elamipretide in the rare indication of mitochondrial dysfunction, a disease for which there no currently approved treatments.
You may also be interested in...
Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
Finance Watch: Dementia Discovery Fund Exceeds Fundraising Goal By $150m
Private Company Edition: The Dementia Discovery Fund started in 2015 with plans to raise $200m to fund early-stage development of disease-modifying drugs, but recently closed its fundraising with $350m in commitments. Also, Kaleido's $101m Series C is among three recent $100m-plus rounds.
Travere’s Filspari US Approval Marks First For IgAN
Travere Therapeutics is aiming to provide a new foundational therapy for IgAN patients with its novel non-immunosuppressive agent, Filspari, as it prices it at a discount to Calliditas’s rival Tarpeyo, ahead of looming further competition.